Drugs / CD34-positive cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00620048 | Mar 2008 → Jan 2011 | congestive heart failure, myocardial ischemia | Losordo, Douglas, M.D. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00616980 Comparator | Dec 2007 → Apr 2010 | limb ischemia, peripheral arterial disease | Losordo, Douglas, M.D. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34-positive cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00620048 ↗ |
| Known as | CD34+ cells | “Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%” NCT00620048 ↗1“intramuscular injections of autologous CD34+ cells in subjects with moderate or high-risk critical limb ischemia” PMID 23192920 ↗ Nov 2012 |
| Modality | Cell therapy | “autologous CD34+ cell therapy” PMID 23192920 ↗ Nov 2012 |
| Route | Intramuscular | “Intramuscular injections were distributed into 8 sites within the ischemic lower extremity” PMID 23192920 ↗ Nov 2012 |